Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q2 2026
Lexicon Pharmaceuticals (LXRX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Lexicon Pharmaceuticals (LXRX) reported revenue of $692K for the second quarter 2026 (Q2 2026), -98% from a year earlier and -97% from the quarter before.
Lexicon Pharmaceuticals, Q2 2026: revenue $692K (-98% year over year), net loss $31.8M, operating cash flow −$9.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $692K | -97% | -98% |
| Operating profit | −$26.5M | — | -810% |
| Net earnings | −$31.8M | — | -1077% |
| Operating cash flow | −$9.2M | — | -154% |
What changed
Revenue was $692K in Q2 2026, down 98% year over year and down 97% from the previous quarter.
Operating costs exceeded revenue by $26.5M, an operating margin of -3835.3%. Total costs grew 8% against a revenue fall of 98%. The fastest-growing cost line was Cost of revenue (+18%). The quarter ended with a net loss of $31.8M, wider than the previous quarter's $1.0M loss.
Operating cash flow was −$9.2M. Non-cash charges added back $102K of depreciation and amortization and $3.3M of share-based compensation. Working capital and other items added $19.1M.
Questions
What was Lexicon Pharmaceuticals' revenue in the second quarter 2026?
Lexicon Pharmaceuticals (LXRX) reported revenue of $692K for the second quarter 2026 (Q2 2026), -98% from a year earlier and -97% from the quarter before.